Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | PHASE1 | COMPLETED | 53 | — | — | Jul 11, 2011 | Feb 22, 2019 | Mar 10, 2022 | 13 | Spain |
The MTD is defined as the dose at wich two of the patients have experienced dose-limiting toxicity.
Response rate is defined as the percentage of patients with complete response or partial response confirmed according RECIST v.1.1
| Arm | Type | Description |
|---|---|---|
| Pazopanib + interferon | EXPERIMENTAL | Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient |
| Name | Type | Description |
|---|---|---|
| Pazopanib + interferon alpha 2A | DRUG | Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient |
Inclusion Criteria: 1. Signed informed consent 2. Age ≥ 18 years. 3. Patients diagnosed histologically clear cell carcinoma of the kidney metastatic or unresectable locally advanced, previously untreated. However, in Phase I may include patients with primary tumors other than renal cell can benefit...